Kristina Jankovic, MD· @JankovicK · X·· 1 天前评分70
正文 · 原文
Impressive #APEXBreast01 data showing benefit with rolditamig deuderuxtecan over first-line chemotherapy in HR+/HER2-low metastatic #BreastCancer!
📌 mPFS: 16.4 vs 5.5 months (HR 0.29)
📌 ORR more than doubled
📌 Encouraging early OS trend
#ESMO26 @OncoAlert
397 浏览 · 9 赞 · 3 转发 · 0 回复
来源：Kristina Jankovic, MD · x.com